clinical trials glp 1 Care Access Retatrutide for weight loss: Study

In 2023, the FDA launched an investigation after GLP-1 agonist users started reporting thoughts of suicide as of January 2024, it hadnt found anything to confirm the connection, but it also said it couldnt yet rule it out, meaning its possible the drugs could cause mental health issues for some people, rather than treating or preventing them

Not fake, not proven, but plausible and monitorable

Businesses can build a strong brand through this method which requires less time and financial resources for building their physical assets

PubMed: 9733836

The announcement shocked health experts because the FDAs usual approval process, which is lengthy and rigorous, has been bypassed